Bristol-Myers Squibb Company (NYSE: BMY) announced that a randomized Phase 3 study evaluating Opdivo (nivolumab) versus investigator’s choice in patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments Trader Talk

Bristol-Myers Squibb (BMY) Tops Q4 EPS by 10cJanuary 28, 2016 7:00 AM CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped EarlyJanuary 28, 2016 6:59 AM Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial ResultsJanuary 28, 2016 6:59 AM